Endogenex, a Minnesota-based developer of endoscopic therapies for type 2 diabetes, has raised $50M in a Series C extension led by Arboretum Ventures. The funding brings the company's total Series C to $138M and supports the pivotal ReCET clinical study of its investigational Endogenex System. This outpatient procedure uses non-thermal pulsed electric fields to target dysfunctional cells in the duodenum, aiming to reset metabolic signaling and improve glycemic control.
GLP-1 Surge Drives Gut Therapies
The raise aligns with surging demand for durable alternatives to GLP-1 drugs, now used by 25% of type 2 diabetes patients. Fractyl Health recently reported positive data from its REMAIN-1 trial for a similar duodenal therapy, validating the approach amid GLP-1 adherence challenges. Endogenex differentiates with non-thermal pulsed electric fields, avoiding risks of thermal ablation used by competitors.
Duodenal Dysfunction Fuels T2D Progression
Type 2 diabetes affects adults inadequately controlled by non-insulin medications, where duodenal signaling dysfunction contributes to insulin resistance. Current therapies like GLP-1s manage symptoms but fail to address root causes like diabetic duodenopathy. Endogenex targets these cells to promote regeneration and slow disease progression.
Non-Thermal PEF Resets Metabolic Signaling
The Endogenex System delivers precise pulsed electric fields via endoscopy to eliminate dysfunctional duodenal cells without heat damage. Feasibility studies REGENT-1 and EMINENT showed 1.5% HbA1c reduction, 5.4kg weight loss, and time-in-range up to 82.1% at 48 weeks. This dose-dependent response supports single-procedure durability versus ongoing injections.
As Endogenex CEO Stacey Pugh noted:
"This financing puts us in a strong position to complete our pivotal study and take the ReCET System through FDA approval."
Medtech VCs Bet on Endoscopic Reset
Arboretum Ventures led the extension, joined by Hatteras Venture Partners, Lumira Ventures, Orlando Health Ventures, and Intuitive Ventures. These investors bring medtech expertise, with Intuitive's focus on endoscopy and Arboretum's track record in device exits like NxThera to Boston Scientific. The mix signals conviction in Endogenex's path through FDA Breakthrough Designation and pivotal trial.
Diabetes Devices Market Accelerates
The diabetes care devices market stands at $34.3B in 2025, projected to reach $61.2B by 2030 at 12.3% CAGR. Endoscopic metabolic therapies emerge as a niche, fueled by GLP-1 limitations and interest in gut-targeted interventions. Endogenex's FDA IDE approval in November 2023 positions it ahead in this shift.
Serial Medtech Leaders Drive Execution
CEO Stacey Pugh brings Medtronic Neurovascular presidency experience, while co-founder Michael Brenzel led acquired Conventus Orthopaedics. VP Market Development Brent Collins scaled Torax Medical's LINX device to J&J acquisition, directly relevant to GI endoscopy. New CFO Krissy Wright managed $B-scale P&Ls at Medtronic, bolstering trial funding.
Pivotal Enrollment Powers FDA Path
With first patient enrolled in October 2024 at Orlando Health, the sham-controlled ReCET study spans up to 350 patients across 40 US/Australia sites. The funding extends runway for completion and regulatory submission. Partnerships with Mayo Clinic and recent peer-reviewed REGENT-1 data in the Journal of Diabetes, Obesity and Metabolism strengthen momentum.